Latest ThermoDoxÂ® Stories
ThermoDox® Continues to Demonstrate Impressive Local Response Rate in Highly Refractory Patients LAWRENCEVILLE, N.J., April 15, 2015 /PRNewswire/ -- Celsion Corporation (NASDAQ:
Analysis of 285 Patient Subgroup Shows an Impressive Statistically Significant 59% Improvement in Overall Survival LAWRENCEVILLE, N.J., Feb.
LAWRENCEVILLE, N.J., Jan.
ThermoDox® Combined with Mild Local Hyperthermia is Safe and Produces Compelling Objective Local Responses in RCW Breast Cancer Patients LAWRENCEVILLE, N.J., Sept.
Kyungpook National University Hospital in South Korea Treats the First Patient in the 14 Country, 100 Site Global Study LAWRENCEVILLE, N.J., Sept.
Latest Data Sweep from a 285 Patient Subgroup Shows An Impressive 57% Improvement in Overall Survival LAWRENCEVILLE, N.J., July 28, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ:
- Transaction Forms Fully-Integrated Oncology Discovery and Development Company LAWRENCEVILLE, N.J.
Abstract Presents a Retrospective Analysis of the Company's 701 Patient HEAT Study and Compelling Data Showing Enhanced Efficacy When Radiofrequency Ablation is Combined with ThermoDox and When Heating
Study Developed in Consultation with Clinical Advisors, Statistical Experts and FDA LAWRENCEVILLE, N.J., Feb.